425: AlloVir and Kalaris Therapeutics Announce Merger to Focus on Retinal Diseases

AlloVir and Kalaris Therapeutics have agreed to merge in an all-stock transaction, creating a company focused on developing treatments for retinal diseases, with Kalaris' TH103 as the lead asset.

Summary

• AlloVir and Kalaris Therapeutics have entered into a definitive merger agreement where AlloVir will acquire 100% of Kalaris' outstanding equity interest in an all-stock transaction.
• Post-merger, pre-Merger AlloVir stockholders are expected to own approximately 25.05% of the combined company and pre-Merger Kalaris stockholders are expected to own approximately 74.95% of the combined company, subject to certain adjustments.
• The combined company is expected to have approximately $100 million in cash at closing, anticipated in Q1 2025, providing a cash runway into Q4 2026.
• The combined company will operate under the name Kalaris Therapeutics, Inc. and trade on Nasdaq under the ticker symbol 'KLRS'.
• Kalaris' lead asset, TH103, is a novel anti-VEGF therapy in Phase 1 clinical trial for neovascular age-related macular degeneration (nAMD), with initial data expected in Q3 2025.
• The Phase 1 clinical trial is investigating TH103 in treatment-naive patients diagnosed with nAMD to evaluate safety, PK/PD, determine a maximum tolerated dose, and assess preliminary data supporting the anti-VEGF effect of TH103 on fluid and visual acuity.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the merger is presented as a positive step for both companies, it also acknowledges the challenges faced by AlloVir and the need for a strategic shift. The potential of TH103 and the expertise of the combined team are highlighted, but the risks associated with clinical development and regulatory approval remain.

Positives

• The merger combines AlloVir's financial resources with Kalaris' TH103 asset, potentially accelerating its clinical development.
• TH103 has the potential to be a meaningful advance for patients suffering from neovascular and exudative retinal diseases.
• The combined company is expected to have a cash runway into Q4 2026.
• Kalaris' TH103 has demonstrated longer-acting and increased anti-VEGF activity in head-to-head preclinical studies against aflibercept.
• The combined company will be led by a well-credentialed management team with experience in retinal diseases.

Negatives

• AlloVir stockholders will own a minority stake (approximately 25.05%) in the combined company.
• The merger is subject to stockholder approval and other customary closing conditions, which could delay or prevent the transaction from closing.
• The success of TH103 is not guaranteed, and clinical trial results may not be positive.

Risks

• The merger is subject to stockholder approval and other customary closing conditions, which could delay or prevent the transaction from closing.
• The combined company's cash runway may be shorter than expected if operating expenses are higher than anticipated.
• Clinical trial results for TH103 may not be positive, or regulatory approval may not be obtained.
• The combined company may face competition from other companies developing treatments for retinal diseases.
• The market for anti-VEGF therapies may not grow as expected.

Future Outlook

The combined company is expected to focus on the clinical development of TH103 for neovascular and exudative retinal diseases, with plans to initiate a Phase 2 clinical trial in 2026 and expand into other indications.

Management Comments

• David Hallal, Chairman of the Board of AlloVir, stated that the merger will help accelerate the clinical development of TH103 for nAMD and other diseases.
• Diana Brainard, CEO of AlloVir, believes that Kalaris is strongly positioned with an innovative clinical stage asset with the potential to disrupt the large anti-VEGF market.
• Andrew Oxtoby, CEO of Kalaris Therapeutics, looks forward to reporting initial data in treatment nave nAMD patients in the third quarter of 2025.
• Srini Akkaraju, MD, PhD, Managing Partner of Samsara BioCapital, commented that TH103 may represent a significant advance in the treatment of multiple retinal diseases.
• Napoleone Ferrara, MD, PhD, added that TH103 was specifically engineered to utilize the natural configuration of important domains of VEGF Receptor 1 and has demonstrated both potent anti-VEGF activity and sustained ocular residence time in preclinical studies.

Industry Context

The merger reflects a trend in the biopharmaceutical industry to consolidate resources and expertise to develop innovative therapies for diseases with high unmet needs, particularly in the growing anti-VEGF market for retinal diseases.

Comparison to Industry Standards

• Aflibercept (Eylea) and ranibizumab (Lucentis) are established anti-VEGF therapies with multi-billion dollar sales.
• The press release mentions that the global market for branded anti-VEGF agents is approximately $14 billion and projected to grow to approximately $18 billion by 2029.
• The document highlights that TH103 has demonstrated longer-acting and increased anti-VEGF activity in head-to-head preclinical studies against aflibercept, suggesting a potential competitive advantage.
• Vabysmo, a bispecific antibody targeting VEGF and Ang-2, is a more recent entrant to the market.
• The document notes that real-world patient outcomes with existing anti-VEGF therapies have not replicated the results from registrational clinical trials, suggesting a need for improved therapies.

Management Changes

Stakeholder Impact

• AlloVir stockholders will have a smaller ownership stake in the combined company but may benefit from the potential success of TH103.
• Kalaris stockholders will gain access to AlloVir's financial resources and public market listing.
• Employees of both companies may experience changes in their roles and responsibilities.
• Patients with retinal diseases may benefit from the development of new and improved treatments.

Next Steps

• Obtain stockholder approval from both AlloVir and Kalaris.
• Secure regulatory approvals, including Hart-Scott-Rodino Antitrust Improvements Act.
• File and have declared effective a registration statement with the SEC.
• Close the merger, expected in Q1 2025.
• Advance the clinical development of TH103, with initial data expected in Q3 2025.
• Initiate a Phase 2 clinical trial of TH103 in 2026.
• Potentially expand into other indications such as DME and RVO.

Key Dates